The whiteboard claim does not survive a soil bag
Someone still says Stromectol began as a designed molecule. Open the origin papers and the first object is a plastic bag of Japanese soil, not a structure drawn from first principles.
Satoshi Omura's group at Kitasato did not hunt a river-blindness pill. They collected soil, grew whatever would culture, and asked whether the chemistry those microbes used against rivals might matter to a mammal. Most plates stay blank. The method is grind, not inspiration. Soil bacteria invent weapons; a patient lab files the rare one that does not wreck the host.
Kawana sits southwest of Tokyo, a golf-course verge that would never make a press kit. Mid-1970s, one sample held a Streptomyces no catalogue listed. Later named Streptomyces avermitilis, that single isolate is the ancestor of every ivermectin tablet pressed since. A medicine used across the tropics still rests on one bag and a microbiologist stubborn enough to keep scooping after the unrewarding years.
Strike the origin myth that treats the tablet as a sketch that happened to work. File the organism. Without that isolate there is no 3 mg chip, no Mectizan crate, no Stockholm citation. Later chemistry refined a lead. It did not invent the lead.
Kitasato's slow plates, not a photo-op isolate
Culturing that isolate was not a weekend. Pure plates, stable passage, enough broth to ship - weeks of flasks that look like nothing on a slide. Kitasato had decades of practice pulling useful chemistry from stubborn actinomycetes. The Kawana strain was another slow customer, not a miracle that announced itself.
Tokyo could grow the organism. It could not run industrial parasite screens in livestock and laboratory animals at the scale a development shop needs. Omura sent promising cultures across the Pacific instead of parking them in a freezer. Knowing the limit of your bench and posting the sample was as much of the discovery as the scoop itself.
Claim: Japanese soil work was a footnote to an American drug. Label the split. Without Kitasato there is no organism. Without a partner who can infect and treat animals at volume, a pretty culture stays a pretty culture. The later Nobel split is just that ledger written in gold.
Two desks, one culture crate, one shared prize
A lone-genius plaque is a tidy lie. The tablet required a finder in Tokyo and a tester in the United States working as a pair, not a solo name on a bottle.
| Desk | Omura / Kitasato | Campbell / Merck |
|---|---|---|
| Job | Find and culture the microbe | Screen compounds in infected animals |
| Strength | Rare soil actinomycetes | Parasitology plus development |
| Output | Streptomyces avermitilis isolate | Avermectins flagged as active |
| Later mark | Shared 2015 Nobel | Shared 2015 Nobel |
Cultures crossed the Pacific because Merck had the animal models Omura lacked. William Campbell's parasitology group ran broths through infected hosts, hunting something that killed worms without wrecking the mammal. Material from the Kawana strain threw off avermectins - startling potency at low doses against a spread of parasitic nematodes.
Campbell then kept the hit alive inside a company where most leads die in a quiet meeting. Omura supplied the organism. Campbell proved what it did in living animals and argued for development. Neither half alone becomes a human tablet. Sharing the 2015 Nobel in Physiology or Medicine was the committee naming that split, not a courtesy.
On this desk we file both names on the same card. Drop Omura and you have no strain. Drop Campbell and you have a soil story without a drug. The paper trail is a partnership, which is why a single-hero version keeps failing a fact check.
One 22-23 bond turned a lead into a swallowable mix
| Mark | Natural avermectin | Ivermectin |
|---|---|---|
| Source | Streptomyces avermitilis broth | Lab hydrogenation of a B1 lead |
| Edit | None | Hydrogen at the 22-23 bond |
| Mix | A family of related compounds | Two B1 derivatives, B1a-heavy |
| Use | Potent starting chemistry | More stable, broader, safer margin |
Patients do not swallow raw avermectin. Merck chemists hydrogenated an avermectin at the 22-23 position and produced ivermectin, a mixture of two B1 derivatives (B1a the larger share, B1b the smaller). That edit improved chemical stability, widened antiparasitic reach a notch, and opened a safer margin than the unmodified family.
Hydrogenation at the 22-23 bond is ordinary natural-product work: take a microbial lead, tidy the liability, keep the kill. Calling the result a 'lab invention' erases the organism. Calling it an unchanged bacterial juice erases the chemists. File both. The 3 mg chip is a refined relative of what Streptomyces avermitilis makes, not a photocopy and not a sketch.
Where that finished molecule later succeeded and failed in people is a different file - the trial review, not this origin card. Start at what Strongyloides studies measured when you want endpoints instead of dates.
The 1981 veterinary ledger came first, on purpose
Ivomec hit veterinary shelves around 1981, years before a human label. Cattle, sheep, horses, and dogs - including heartworm prevention - turned the molecule into an animal-health blockbuster. That chapter is not a shameful footnote. It proved kill and tolerance in the field and paid for the human program.
That animal ledger also left concentrated pastes and pour-ons built for bodies of hundreds of kilograms. Decades later, people treated those syringes as a cheap human dose. The misuse is new. The concentration gap is as old as the veterinary launch. A fact line that skips the animal years cannot explain either the funding or the later emergency-room paste cases.
Human approval followed only after the river-blindness work, not because a social feed discovered a livestock secret. Chip counts and fasting rules sit on the 3 mg working card. This page stays with who found what, and in what order.
1987: Vagelos signed a gift with no end date
River blindness pulled the molecule into human use. Blackflies along fast water spread Onchocerca volvulus; larvae scar skin and wreck vision, emptying farmed valleys. Campbell inferred a human use from animal data on a related filarial worm. Trials then showed a single oral dose suppresses the damaging microfilariae for months. Adult worms live on. The public-health job became repeat dosing at community scale.
Roy Vagelos signed an open-ended pledge in 1987: Merck would give ivermectin for onchocerciasis for as long as needed, not for a fixed run of years. The Mectizan Donation Program has since moved billions of treatments and pushed several countries toward elimination. It remains one of the largest sustained drug gifts in the record. Cost was the usual blocker for mass campaigns. An open pledge removed that blocker.
Strike the later claim that the company 'hid' a miracle. The donation is in the minutes. File the political fact too: a tablet only changes a valley if ministries can run the rounds year after year. Chemistry found the molecule. Logistics and an unusual gift put it in the villages.
Stockholm waited until the valleys had emptied
Overnight-breakthrough prizes are a press habit. Ivermectin's Nobel arrived almost four decades after the Kawana scoop, which is how this prize often behaves when the stake is a neglected infection.
Omura isolates a new Streptomyces from soil near a Kawana golf course; the strain is later named S. avermitilis.
Campbell's Merck group screens the cultures and flags avermectins as highly active against parasitic worms.
Hydrogenated ivermectin launches as a veterinary antiparasitic and becomes a top animal-health seller.
Human use for river blindness; Merck begins the open-ended Mectizan Donation Program.
Omura and Campbell share the Nobel Prize in Physiology or Medicine for the avermectins.
October 2015 split Physiology or Medicine three ways: Omura and Campbell for the avermectins, Tu Youyou for artemisinin. The committee framed one idea - therapies drawn from nature that changed devastating parasitic disease. For a field that works far from headlines, it was a rare turn in the light. The long wait is part of the method. The prize tends to hold until real-world impact is past argument. By 2015 the Mectizan record was past argument.
The wait is the method. Committees that reward a press cycle would have spoken in the 1980s. Committees that wait for emptied valleys spoke in 2015. That delay is a feature if you care about lasting effect, and a frustration if you wanted a faster plaque. On this desk we file the delay as evidence, not as a snub.
Step back and the trail is honest about where some medicines still come from. Not a screen-designed scaffold. A bacterium in the ground, a collector who did not quit, a partnership across an ocean, a one-bond tidy-up, an animal ledger, then a gift large enough to change maps. The same patient natural-product habit gave us a large share of antibiotics. Hold that when later threads try to stretch the tablet past worms.
What a Manchester desk files from this trail
What this desk files from the trail is short. Claim of a whiteboard drug: struck. Label: one unrecovered Kawana isolate, a 22-23 hydrogenation, animals first, then an open 1987 gift, then a 2015 prize that waited for impact. File those dates. Do not file a lone hero or a conspiracy about a hidden cure.
Read the finished pharmacology on the Stromectol 3 mg reference when you need channels, half-life, and labeled jobs. Read the trial review when you need stool-cure numbers versus empty viral endpoints. This page is the paper trail only. Bring a worm name to your own clinician before anyone counts chips.